Answers are grounded in this paper and cite their sources.
Background/Objectives: The clinical significance of 18F-fluorodeoxyglucose (FDG) uptake in well-differentiated pulmonary neuroendocrine tumors (WD-PulNETs) remains uncertain. We assessed the prevalence of FDG positivity in routine clinical practice. Methods: This multicenter retrospective cohort included histologically confirmed typical or atypical pulmonary carcinoids. FDG PET/CT was classified as positive or negative according to the original nuclear-medicine report. Results: Of 91 WD-PulNETs patients, 81 had sufficient data for analysis. The cohort included 67 patients (82.7%) with typical carcinoids and 14 (17.3%) with atypical carcinoids. FDG PET/CT was performed in 50 patients (61.7%), of whom 46 (92.0%; 95% CI, 81.2–96.8%) had report-defined FDG positivity in the primary pulmonary tumor. FDG positivity was observed in 39 of 42 patients (92.9%) with typical carcinoids and 7 of 8 (87.5%) with atypical carcinoids. Comparisons between patients who underwent FDG PET/CT and those who did not revealed no statistically significant differences in most evaluated clinicopathological characteristics. However, somatostatin analogue treatment was more frequent among patients who underwent FDG PET/CT (35.6% vs. 7.7%; p = 0.011). Conclusion: Report-defined FDG positivity was highly prevalent across the spectrum of WD-PulNETs, including typical carcinoids. Potential selection bias and the small number of patients preclude firm conclusions about its discriminatory or prognostic significance.
No takes yet. Share an insight, caveat, or question.
Muzykovskaia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: